The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
lu suo li ti ni de yao li yu lin chuang yan jiu
Author(s): 
Pages: 1233-1235+1241
Year: Issue:  11
Journal: Chinese Journal of New Drugs

Keyword:  ruxolitinib.The pharmacologypharmacokineticsdrug interactionsclinical study and safety of ruxolitinib was reviewed in this paper. [Key words] ruxolitinibmyelofibrosispharmacologyclinical study;
Abstract: 鲁索利替尼为一种可口服给药的选择性JAK1/JAK2激酶抑制剂,是首个被美国FDA批准用于骨髓纤维化治疗的药物。本文通过文献检索,对其药理作用、药动学、药物相互作用、临床研究和安全性进行了综述。
Related Articles
No related articles found